Online inquiry

IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15459MR)

This product GTTS-WQ15459MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets ERBB3 gene. The antibody can be applied in Breast Cancer, Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001005915.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2065
UniProt ID P21860
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15459MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3995MR IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BGB-A317
GTTS-WQ6184MR IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CP-870893
GTTS-WQ9114MR IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA IMGN242
GTTS-WQ12612MR IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OMNITARG™
GTTS-WQ9298MR IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IMMU-132
GTTS-WQ13118MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PF-04360365
GTTS-WQ15241MR IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA TAK-079
GTTS-WQ3427MR IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AV-299
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW